FDA Law Blog

JANUARY 15, 2024

By David B. Clissold & Sara W. Koblitz — You know a court decision is going to be worth reading when the judges compare FDA’s regulatory governance of flavored e-cigarettes to a Shakespearean gaslighting. To quote the Fifth Circuit: “It was the regulatory equivalent of Romeo sending Mercutio on a wild goose chase—and then admitting there never was a goose while denying he even suggested the chase.

Manufacturing 115

Manufacturing IT Provider ER 115

The Clinical Problem Solvers

JANUARY 17, 2024

[link] Episode title: Episode 317: Neurology VMR – Generalized weakness Episode description: We continue our campaign to #EndNeurophobia, with the help of Dr. Aaron Berkowitz. This time, Kirtan presents a case of generalized weakness to Vivek and Hannah. Neurology DDx Schema Kirtan Patolia @KirtanPatolia Kirtan Patolia is a second-year Internal Medicine resident from John H.

Internal Medicine 52

Internal Medicine Diagnose Clinic Hospital 52

GeriPal

JANUARY 18, 2024

Summary Transcript Summary The CDC’s Guideline for Prescribing Opioids for Chronic Pain excludes those undergoing cancer treatment, palliative care, and end-of-life care. In doing so, it seems to give the impression that pain seen in cancer is inherently different than pain seen in other conditions and that those with cancer may not have the same risk for opioid use disorder as compared to other conditions.

Illness 136

Illness Patient-Centered Screening IT 136

PEMBlog

JANUARY 17, 2024

This episode will help you recognize cellulitis and even differentiate it from erysipelas which is totally a different thing. You’ll also learn about treatment, whether or not a blood culture is necessary, and a whole lot more. @PEMTweets on… sigh “X” (Twitter) My Instagram My Mastodon account @bradsobo Listen [link] Subscribe References Chen AE, Carroll KC, Diener-West M, Ross T, Ordun J, Goldstein MA, Kulkarni G, Cantey JB, Siberry GK.

IT 59

IT Patients Diagnosis Clinic 59

FDA Law Blog

JANUARY 18, 2024

By John W.M. Claud & Sara W. Koblitz & Karla L. Palmer — A new lawsuit against FDA is the latest happening in the veterinary drugs space and, by extension, FDA’s Center for Veterinary Medicine (CVM). We blogged about CVM last week and explained the increasing attention to animal health products due to the expansion of the animal and pet product market.

IT 59

IT 59

FDA Law Blog

JANUARY 18, 2024

By Larry K. Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By doing so, FDA determined that marijuana not only no longer meets schedule I criteria, but by leapfrogging to schedule III, concluded that it does not meet schedule II criteria either.

Medical 69

Medical Physicals IT Healthcare Professional 69